Topic Highlight
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 28, 2014; 20(28): 9253-9260
Published online Jul 28, 2014. doi: 10.3748/wjg.v20.i28.9253
Hepatitis C virus reinfection after liver transplantation: Is there a role for direct antiviral agents?
Marco Dall’Agata, Annagiulia Gramenzi, Maurizio Biselli, Mauro Bernardi
Marco Dall’Agata, Annagiulia Gramenzi, Maurizio Biselli, Mauro Bernardi, Semeiotica Medica - Policlinico S. Orsola-Malpighi, Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna, 40138 Bologna, Italy
Author contributions: All authors contributed equally to this work; Dall’Agata M, Gramenzi A and Biselli M put forward the conception and design of the work, acquisition of data, analysis and interpretation of data, drafting and revision of the manuscript, work supervision, approval of the final version of the manuscript; Bernardi M contributed to conception of the work, interpretation of data, drafting and revision of the manuscript, work supervision, approval of the final version of the manuscript.
Correspondence to: Mauro Bernardi, MD, Professor, Director, Semeiotica Medica - Policlinico S. Orsola-Malpighi, Dipartimento di Scienze Mediche e Chirurgiche, University of Bologna, Via Albertoni 15, 40138 Bologna, Italy. mauro.bernardi@unibo.it
Telephone: +39-51-6362939 Fax: +39-51-6362930
Received: October 15, 2013
Revised: March 27, 2014
Accepted: June 2, 2014
Published online: July 28, 2014
Core Tip

Core tip: Considering the increasing shortage of donor organs and the accelerated progression of hepatitis C (HCV) in liver transplant recipients, the development of effective strategies to treat HCV recurrence are of paramount importance. The new classes of direct antiviral agents (DAAs) improved the results of antiviral therapy in HCV-infected immunocompetent patients. The aim of this review was to identify and summarize the potential benefit of DAAs in the liver transplant setting.